Suven Life Sciences, a specialty biopharmaceutical company developing therapeutics in Central Nervous System diseases, today announced that the last patient has completed the last visit for its Phase 2 POC study of SUVN-502 for moderate Alzheimer's disease.
The company expects to report the top-line data of this study at Alzheimer's Association International Conference (AAIC) on 17th July 2019 at Los Angeles.
This randomized, double-blind, placebo-controlled study is evaluating the efficacy and safety of two doses of Masupirdine (SUVN-502) in moderate Alzheimer's Disease patients who are taking both Aricept (donepezil) and Namenda (memantine). Study duration is 30 weeks. This is the first ever study to evaluate a triple combination therapy for moderate Alzheimer's disease patients.
There is an urgent need for treatment options for patients with Alzheimer's disease (AD) dementia since there are no new drugs discovered or developed since 2003.
We are very pleased to have completed last patient last visit (LPLV) and completing this trial represents a significant milestone for the development of our lead compound Masupirdine (SUVN-502) in this Phase 2 study in moderate Alzheimer's disease and moves us a step closer to potentially bringing this new treatment option for people afflicted with moderate Alzheimer's disease globally.
Shares of SUVEN LIFE SCIENCES LTD. was last trading in BSE at Rs.251.05 as compared to the previous close of Rs. 253.1. The total number of shares traded during the day was 25451 in over 642 trades.
The stock hit an intraday high of Rs. 255 and intraday low of 250. The net turnover during the day was Rs. 6433175.